Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade.
Julie E SteinEvan J LipsonTricia R CottrellPatrick M FordeRobert A AndersAshley Cimino-MathewsElizabeth D ThompsonMohamad E AllafMark YarchoanJosephine FelicianoHao WangElizabeth M JaffeeDrew M PardollSuzanne L TopalianJanis M TaubePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
irPR features are consistent across tumor types and treatment settings. Standardized, pan-tumor irPR criteria (irPRC) are defined and associated specimen-handling considerations are described. Future, prospective studies are merited to validate irPRC in larger datasets and to associate pathologic features with long-term patient outcomes.